- Home
- ADAP vs RPTX Comparison
ADAP vs RPTX Comparison
Compare ADAP & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- RPTX
- Stock Information
- Founded
- ADAP 2008
- RPTX 2016
- Country
- ADAP United Kingdom
- RPTX Canada
- Employees
- ADAP N/A
- RPTX N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- RPTX Health Care
- Exchange
- ADAP Nasdaq
- RPTX Nasdaq
- Market Cap
- ADAP 75.5M
- RPTX 64.8M
- IPO Year
- ADAP 2015
- RPTX 2020
- Fundamental
- Price
- ADAP $0.08
- RPTX $1.50
- Analyst Decision
- ADAP Hold
- RPTX Strong Buy
- Analyst Count
- ADAP 6
- RPTX 3
- Target Price
- ADAP $1.02
- RPTX $4.50
- AVG Volume (30 Days)
- ADAP 18.4M
- RPTX 724.4K
- Earning Date
- ADAP 08-11-2025
- RPTX 08-12-2025
- Dividend Yield
- ADAP N/A
- RPTX N/A
- EPS Growth
- ADAP N/A
- RPTX N/A
- EPS
- ADAP N/A
- RPTX N/A
- Revenue
- ADAP $179,639,000.00
- RPTX $1,073,000.00
- Revenue This Year
- ADAP N/A
- RPTX N/A
- Revenue Next Year
- ADAP $38.72
- RPTX N/A
- P/E Ratio
- ADAP N/A
- RPTX N/A
- Revenue Growth
- ADAP 878.53
- RPTX N/A
- 52 Week Low
- ADAP $0.08
- RPTX $0.89
- 52 Week High
- ADAP $1.36
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- ADAP 25.83
- RPTX 50.25
- Support Level
- ADAP $0.08
- RPTX $1.50
- Resistance Level
- ADAP $0.36
- RPTX $1.62
- Average True Range (ATR)
- ADAP 0.02
- RPTX 0.07
- MACD
- ADAP -0.02
- RPTX -0.01
- Stochastic Oscillator
- ADAP 1.38
- RPTX 41.94
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.